Such novel approaches are urgently needed as it is clear that melanoma cells possess multiple mechanisms to bypass, or overcome drug resistance to agents with clinical success such as PLX4032 (Vemurafenib), a drug targeting mutant BRAF [9,28]. Here, BRAF is linked to melanoma.